It is 2020, do you know what your vendors/suppliers/contract manufacturing organizations are doing?

Companies that use contract manufacturing organizations (CMOs) are ultimately responsible for ensuring product quality and compliance with GMPs. Thus, it pays in more ways than one to be aware of recent FDA quality-related citations at CMOs and other vendors. 

Below is a sample of FDA observations pulled from recent Warning Letter summaries. Special thanks to Govzilla’s Barbara Unger for summarizing these.

Stason Pharmaceuticals

On July 8, FDA issued a Warning Letter to Stason Pharmaceuticals, a contract development and manufacturing organization specializing in clinical trial materials and products under preparation for commercial launch, with, as Barb described, “the most granular list of requested data integrity remediation activities that I’ve seen FDA provide, to date.” The Warning Letter was issued following an Oct. 9-25 inspection.

Investigators cited two major issues: failure to thoroughly investigate batch records and data integrity. For the latter, lack of appropriate controls for ensuring only authorized changes to production and control records served as a major focus. In particular, the investigators found that a computer operating a spectrophotometer used for finished product release and stability testing was not secured and data files could potentially be deleted without the awareness of the quality unit.

Homeocare Laboratories Inc. 

While OTC homeopathic product manufacturer Homeocare Laboratories is not a contract manufacturing organization/supplier, their June 22 Warning Letter included a citation regarding the use of unapproved vendors.

FDA cited the company for not qualifying suppliers nor testing incoming raw materials and components although said materials and components were accepted on the supplier Certificate of Analysis. During the actual inspection, the firm stated that vendors had not actually completed the vendor survey yet in response to the resulting 483, the firm indicated that surveys had been completed.  

Vega Life Sciences Private Limited

FDA issued a Warning Letter dated June 17 to Vega Life Science Private Limited, a contract solvent recovery facility for manufacturing APIs. Additionally, the FDA issued an import alert for the firm preventing it from conducting solvent recovery operations for the U.S. market. 

In addition to data integrity concerns centered on shared passwords, missing raw data, failure to back up data, and inadequate audit trail management, investigators cited failures to evaluate impurities and inadequate cleaning procedures. Notably, investigators found that cleaning procedures were insufficient to prevent carryover, or “contamination for non-dedicated equipment used to recover spent solvents.”

Here, FDA recommended the firm conduct an extensive data integrity remediation and hire a qualified CGMP consultant. 

Samchundang Pharm Co. Ltd.

A Warning Letter was issued May 13 for Samchundant Pharm Co. Ltd. This site functions as both a contract manufacturer and manufactures the company’s own products. 

A number of the deficiencies cited in the Warning Letter fell under failure to follow SOPs or inadequate SOPs. Test methods, notably sterility tests and stability tests, were not established as suitable. The suitability of the in-process bioburden test was also not determined. Investigators deemed the systems for environmental monitoring in the aseptic area inadequate, and the company failed to ensure that personnel involved in manufacturing had the relevant education, training, and experience to perform their tasks. 

In the end, the company ceased production of product for the U.S. market. 

International Trading Pharm Lab Inc

Contract testing laboratory International Trading Pharm Lab received a Warning Letter on April 24. This Warning Letter cited numerous quality testing and data integrity failures. In addition to concerns about access and controls for computerized systems, investigators found that retests had been conducted and these second sets of data were not recorded.

This Warning Letter included a recommendation the company hire a qualified consultant for data integrity remediation and also encouraged quality personnel review FDA’s data integrity guidance.

For a more detailed analysis of this Warning Letter, click here.

Kumar Organic Products Limited

An inspection ending Nov. 14 led to a Warning Letter issued for Kumar Organic Products Limited on April 23. Kumar Organic Products produces an API that serves as an in-process material for a finished drug product. FDA highlighted two main areas of concern: deficiencies in the water system that could potentially enable biofilm formation and failure to test the identity of incoming components nor validate/establish the reliability of supplier data.

FDA recommended the firm hire a qualified CGMP consultant to assist in remediation efforts.

[NOTE: Stay on top of your vendor quality! Get your FREE 483 Observation Report and find out if any of your vendors have received 483 observations. Learn more here.]

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic
Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff

Panel Discussion – Remote Audits

Panel Discussion opt in image

Tuesday, May 18, 2021
10:30 AM PST / 1:30 PM EST

Secure your spot for this informative 1-hour Panel Discussion among experts sharing their thoughts and perspectives on Remote Audits.

Can’t make the discussion?Register and we will send you a post-show recording.

Panelists:
Barbara W. Unger, Unger Consulting, Inc.
Jerry Chapman, Redica Systems
Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections
Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.